PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
OMB OMB
Total number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

Complete if Known			
Application Number	10/613,783		
Filing Date	July 3, 2003		
First Named Inventor	Michel PAIRET et al		
Art Unit	To be assigned		
Examiner Name	To be assigned		
Attorney Docket Number	1/1192-1-C1		

	U.S. PATENT DOCUMENTS					
Examiner Initials		Document Number Number - Kind Code ² (If known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
ESO		us- 2002/0052312 A	05/02/2002	BACH, Mark A. et al	riquies Appear	
ESQ		us- 5,610,163	03/11/1997	R. Banholzer et al.		
		US-				
		us-				
		US-				
		US-				
		us-	***************************************			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		The state of the s	***************************************	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			**************************************	
		US-				

FOREIGN PATENT DOCUMENTS						
	Cite No. ¹	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
_ESO		WO 01 78741 A1	10/25/2001	Glaxo Group Ltd.	· · · · · · · · · · · · · · · · · · ·	┢
ESO		WO 02 09689 A1 -	02/07/2002	Smithkline Beecham	h-14	ļ-·-
ESO		WO 01 57025 A1 -	08/09/2001	Pfizer Products Inc.		
ESO		WO 01 46151 A1	06/28/2001	Merck Frosst Canada		
ESO		EP 1 040 829 A2 🗸	10/04/2000	Pfizer Inc.		
_ESO		WO 00/35428	06/22/2000	Boehringer Ingelheim Pharma KG		
		***************************************			*	

Examiner	/mmi = 01 === /	l Data	00/00/000
0	/Eric Olson/	Date	08/22/2006
Signature	, ====,	Considered	00/22/2000
		CONSIDERED	

English telligibles Translation is attention.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 10/613,783 **Application Number** INFORMATION DISCLOSURE July 3, 2003 Filing Date Michel PAIRET et al To be assigned First Named Inventor STATEMENT BY APPLICANT Group Art Unit (use as many sheets as necessary) Examiner Name To be assigned Attorney Docket Number 1/1192-1-C1 Sheet 2 of 2

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2	
ESO		DISSE, B. et al: "BA 679 BR, A Novel Long-Acting Anticholinergic Bronchodilator: LIFE SCIENCES, Pergamon Press, Oxford, GB, Bd. 5/6, Nr. 52, 1993, Seiten 537-544, XP00800 <u>25</u> 89 ISSN: 0024-3205		
ESO	V	BARNES, P.J.: "Nonantimicrobial Aspects of Therapy" SEMINARS IN RESPIRATORY INFECTIONS, Grune and Stratton, Orlando, US, Bd. 15, Nr. 1, 2000, Selten 52-58 XP000911165, ISSN: 0882-0546, Seite 53, Spalte 1, Absatz 2 - Seite 56, Spalte 1, Zeile 20-40		
ESO		TAVAKKOLI, A., REES, P.J.: "Drug Treatment of Asthma in the 1990s: Achievements and New Strategies" DRUGS, Bd. 57, Nr. 1, 1999, Seiten 1-8 XP001098314 ISSN: 0012-6667 Seite 3, Spalte 2, Abstaz 2; Seite 4, Spalte 2, Abstaz 2		
ESO	<i>ر</i>	DATA BASE WPI Derwent Publications Ltd., London, GB; AN 2001-626119 XP002212897 MATSUMOTO, Tatsumi, TARUI, Naoki et al.: "New and Know Furoisoquinoline Compounds as Phosphodiesterase IV Inhibitors"		

Examiner	/Eric Olson/	Date	08/22/2006
Signature		Considered	00/22/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.